Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.58 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132328 | 0.89 | SPHK2 (0.59) | SPHK2SPHK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1548365 | 0.87 | SPHK2 (0.57) | SPHK2SPHK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12936225 | 0.86 | KMT2A (0.55) | SPHK2SPHK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1548744 | 0.86 | HSD11B1 (0.66) | KMT2AMEN1LMNAHSD11B1POLB | |
| SCHEMBL2253976 | 0.86 | HSD11B1 (0.66) | KMT2AMEN1LMNAHSD11B1POLB | |
| SCHEMBL1548732 | 0.85 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2LMNAHSD11B1 | |
| SCHEMBL417886 | 0.85 | MEN1 (0.72) | KMT2AMEN1SMN1; SMN2LMNAHSD11B1 | |
| SCHEMBL13186412 | 0.84 | POLB (0.54) | KMT2AMEN1SMN1; SMN2LMNAHSD11B1 | |
| SCHEMBL20677900 | 0.83 | SPHK2 (0.46) | SPHK2SPHK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1548098 | 0.83 | POLB (0.61) | SPHK2SPHK1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113574068-B | Method of inducing an anti-cancer immune response | 艾宝奇生物工艺有限公司 | 2024-07-23 | — | — | CN | claimed |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD (IL) | 2024-04-04 | — | — | US | claimed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | claimed |
| CN-116217468-A | Novel synthesis method of opanib | 天津民祥药业有限公司 | 2023-06-06 | — | — | CN | claimed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | claimed |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | REDHILL BIOPHARMA LTD (IL) | 2021-12-02 | — | — | US | claimed |
| CN-113574068-A | Method for inducing anti-cancer immune response | 艾宝奇生物工艺有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | claimed |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | REDHILL BIOPHARMA LTD (IL) | 2021-05-06 | — | — | US | claimed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | claimed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | claimed |
| US-20170252311-A1 | SPHINGOSINE KINASE INHIBITORS AND CERAMIDE FOR MAINTENANCE THERAPY OF GLIOBLASTOMA | SIGNPATH PHARMA INC. | 2017-09-07 | — | — | US | claimed |
| EP-3209290-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | Redhill Biopharma Ltd. (IL) | 2017-08-30 | — | — | EP | claimed |
| WO-2017060771-A2 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-13 | — | — | WO | claimed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | claimed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | claimed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | claimed |
| EP-1904439-A2 | SPHINGOSINE KINASE INHIBITORS | Apogee Biothechnology Corporation (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885SPHK1 1/4885KMT2A 3321/4885 |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | EIF2AK2, RNMT, FBL | SPHK2 1080/4885SPHK1 1082/4885KMT2A 3054/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | SPHK2 1/4885SPHK1 2/4885KMT2A 3422/4885 |
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | SPHK2 2590/4885SPHK1 1279/4885KMT2A 245/4885 |
| US-11633385-B2 | Combination compositions for treatment of cancer | KRAS, TPMT, CYP2D6 | SPHK2 2517/4885SPHK1 1271/4885KMT2A 481/4885 |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | KRAS, TPMT, CYP2D6 | SPHK2 2517/4885SPHK1 1271/4885KMT2A 481/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | SPHK2 2538/4885SPHK1 1258/4885KMT2A 425/4885 |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | SPHK2, SPHK1, S1PR2 | SPHK2 1/4885SPHK1 2/4885KMT2A 3422/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | SPHK2 1420/4885SPHK1 975/4885KMT2A 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.